Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

The three companies' decisions were spurred by concerns about potential for the bone disorder avascular necrosis.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet